Raymond T. Chung, MD
Associate Professor of Medicine,
Harvard Medical School
Director of Hepatology
Medical Director,
Liver Transplant Program
Massachusetts General Hospital
| Address: | Massachusetts General Hospital Blake 4 55 Fruit St. Boston, MA 02114 |
| Patient Appointments: | (617) 724-6006 |
| Academic Phone: | (617) 724-7562 |
| Fax: | (617) 724-6832 |
| E-Mail: | rtchung@partners.org |
| Education: | |
| MD Degree: | Yale University School of Medicine, 1986 |
| Residency: | Johns Hopkins Hospital, 1989 |
| Fellowship: | Massachusetts General Hospital |
Clinical Interests:
Hepatitis C Virus
Viral Hepatitis
Liver Transplantation
Hepatology
HIV
Research Interests:
My main interest has been studies of the biology of hepatitis C virus infection., the leading cause of chronic liver disease in the U.S. The major impediment to meaningful advances in the understanding of this important human pathogen has been the lack of tractable tissue culture or small animal models. Our laboratory has successfully developed a cell-based model that recapitulates the early steps of the viral lifecycle. We are currently engaged in investigation seeking to characterize the host response to viral replication at the mRNA and the protein level, so that a more complete picture of viral pathogenesis and carcinogenesis can be drawn.
We are also conducting bench and clinical investigation on the interactions of HCV with the host immune system in several contexts: acute HCV infection, HCV-HIV coinfection, and post-liver transplantation HCV infection, so that the role of the host in progression of HCV-related liver disease can be better defined.
Recent Publications:
- Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):422-3.
- Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis. 2004;189(8):1472-81.
- Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, Bhan A, Baid S, Cosimi AB, Pascual M, Chung RT. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation. 2004; 77(5):703-10.
- Hiasa Y, Kamegaya Y, Nuriya H, Onji M, Kohara M, Schmidt EV, Chung RT. Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma. Am. J Gastroenterol. 2003; 98(11):2528-34.
- Somsouk M, Lauer GM, Casson D, Terella A, Day CL, Walker BD, Chung RT. Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterol. 2004; 126(2):627.
- Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS.2002; 16(14):1915-23.
- Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.J Virol. 2002; 76(17):8505-17.
- Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, Wang TC, Schmidt EV. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci U S A. 2001; 98(17):9847-52.
